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Knocking out barriers to 
engineered cell activity
CRISPR-Cas9 gene-edited T cells  show safety and long-
term engraftment in humans
By Jennifer R. Hamilton 1,2 and Jennifer A. Doudna 1,2,3,4,5,6,7
Engineered T cell therapies are revolutionizing cancer treatment by achieving long-lasting remission in
blood-related cancers, such as leukemia and lymphoma. These therapies involve removal of patient T
cells, “reprogramming” them to attack cancer cells, and then transferring them back into the patient.
Targeted gene inactivation (knockout) using CRISPR-Cas9 can enhance T cell activity (1, 2) and has the
potential to expand cell therapy applications. Until now, it has been unknown whether CRISPR-Cas9–
edited T cells would be tolerated and thrive once reinfused into a human. On page XXX of this issue,
Stadtmauer et al. (3) present data from a phase 1 clinical trial (designed to test safety and feasibility) on
the first cancer patients treated with CRISPR-Cas9–modified T cells. The findings represent an important
advance  in  the  therapeutic  application  of  gene  editing  and  highlight  the  potential  to  accelerate
development of cell-based therapies.
The production of engineered cell therapies involves transduction of isolated patient T cells with a
disarmed virus to express a receptor recognizing an antigen present on the outside of cancer cells
(through chimeric antigen receptors, CARs) or on the inside of cancer cells [through T cell receptors
(TCRs) specific for cancer-associated peptides]. Once transduced, the engineered T cell population is
expanded and then reinfused back into the patient. Although highly effective at treating some types of
cancer, the specificity and longevity of engineered T cell activity can be improved. For example, T cell
activity  is  naturally  down-regulated  through the  programmed cell  death  protein  1  (PD-1)  receptor.
Systemic inhibition of PD-1 in patients can enhance T cell activity but often triggers adverse autoimmune
reactions. Additionally, endogenous TCR expression competes with the transgenic receptor in engineered
T cells, interfering with signaling or cell trafficking. Genetic knockout of the TCR and PDCD1 (the gene
encoding PD-1) can enhance engineered human T cell activity in preclinical human tumor xenograft
models in mice (4,  5). Stadtmauer  et al. tested whether patient-derived T cells containing these gene
knockouts generated by CRISPR-Cas9 are safe and persistent upon reinfusion into humans.
Six patients with either myeloma or sarcoma were enrolled in the trial, and three met the study’s
criteria for T cell reinfusion. A two-step process was used to achieve both native TCR and PDCD1 gene
knockout and transgenic TCR expression in the engineered cells (see the figure). In the first step, isolated
patient T cells were electroporated with preformed ribonucleoproteins (RNPs) of Cas9 protein and guide
RNA  that  targets  the  endogenous  TCR—TCR𝛼 (TRAC)  and  TCR𝛼 (TRBC)—and  PDCD1 for  genetic
disruption. In the second step, cells were transduced with a viral vector to express the transgenic TCR,
which recognizes cancer-testis  antigen 1 (NY-ESO-1),  and expanded in culture to create NY-ESO-1
transduced CRISPR 3X edited (NYCE) cells. Notably, NYCE cells eliminated NY-ESO-1–expressing cells
more effectively than T cells  expressing the NY-ESO-1 TCR alone,  as would be expected from the
successful knockout of the endogenous TCR. 
NYCE cells successfully engrafted in all patients and were detected up to 9 months after reinfusion.
According to  the  authors,  this  persistence  compared favorably  to  the ~1-week half-life  of  infused,
unedited  T  cells  expressing  NY-ESO-1  TCR  in  previous  trials.  NYCE  cells  reisolated  from  a  study
participant also had gene expression profiles consistent with central memory cells, a mark of stable
engraftment. This result contrasts with past studies in which unedited cells expressing NY-ESO-1 TCRs
displayed markers of T cell exhaustion (6). Together, the CRISPR-Cas9 disruption of endogenous TCR and
PD-1 improved the cell-killing ability of the engineered T cells and promoted long-term persistence. 
But are CRISPR-Cas9–edited cells safe in humans? It has been unclear whether Cas9-edited cells will
be immunogenic and whether  residual  Cas9—a bacterial  protein—will  trigger an immune response.
Stadtmauer  et  al.  report  no  editing-associated  toxicity  of  the  NYCE  cells  in  the  three  patients.
Furthermore, although study participants had preexisting T cells and antibodies specific for Cas9 protein
[as observed previously (7)], antibody titers did not increase from baseline over the course of the study.
The lack of a Cas9 immune response could be attributed either to immunosuppression of the patients
receiving NYCE cells, or to the delivery of Cas9 as a nonviral, preformed RNP, which has a limited half-life
in  cells  compared  to  viral  delivery  where  Cas9  protein  is  continuously  expressed  in  treated  cells.
Stadtmauer  et al. also report minimal off-target editing by CRISPR-Cas9, and the ≤1% of NYCE cells
containing chromosomal translocations decreased in patients after reinfusion. Together, these findings
provide a guide for the safe production and nonimmunogenic administration of gene-edited somatic cells.
The big question that remains unanswered by this study is whether CRISPR-edited, engineered T cells
are effective against advanced cancer. Phase 1 trials assess safety, so the efficacy of the NYCE cells for
treating patients was not evaluated. At the end of the study, one participant had died because of cancer
progression  and  the  other  two were receiving  other  therapies.  Although the  efficacy  of  the  Cas9-
engineered cells is thus ambiguous, the authors point out that their study was restricted to editing
protocols available in 2016, when the U.S.  Food and Drug Administration reviewed the clinical  trial
application. Gene disruption efficiencies in this study were modest (15 to 45%), whereas protocols now
exist for reliably achieving >90% gene disruptions in human T cells using Cas9 RNPs (8, 9). Moreover,
recent efforts have demonstrated CAR transgene insertion at the TRAC gene in human T cells, resulting
in simultaneous knockout of the endogenous TCR while driving CAR expression by the native promoter
(8,  10).  Advances  in  generating precise genetic  modifications,  as  well  as  other  choices  of  cancer-
associated targets,  could enhance the efficacy of engineered T cells for the treatment of additional
cancers, including solid tumors, which have largely been resistant to the activity of engineered cell
therapeutics. 
The clinically validated long-term safety of CRISPR-Cas9 gene-edited cells reported by Stadtmauer et
al. paves the way for next-generation cell-based therapies. Although the safety of other types of gene-
edited somatic cells, such as stem cells, remains to be determined, encouraging results show healthy
blood production in the first β-thalassemia and sickle cell anemia patients infused with cells modified by
CRISPR-Cas9 (11). As more gene-based therapies are demonstrated to be safe and effective, the barrier
to clinical translation will become cell manufacturing and administration. A restructuring of production
processes for engineered cells and new CRISPR-Cas9 delivery strategies for the modification of targeted
cells in the body are now imperative to reduce cost and make these revolutionary therapies accessible to
all who can benefit.
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